BLK-IN-2

• CAT Number: I044057
• CAS Number: 2694871-86-6
• Molecular Formula: C39H41N9O3
• Molecular Weight: 683.80
• Purity: ≥95%
• Synonyms: N-[3-[[2-[3-[[1-[(E)-4-(dimethylamino)but-2-enoyl]piperidin-4-yl]amino]anilino]pyrimidin-5-yl]carbamoyl]-4-methylphenyl]isoquinoline-6-carboxamide
• InChI: InChI=1S/C39H41N9O3/c1-26-9-12-33(44-37(50)28-10-11-29-23-40-16-13-27(29)20-28)22-35(26)38(51)45-34-24-41-39(42-25-34)46-32-7-4-6-31(21-32)43-30-14-18-48(19-15-30)36(49)8-5-17-47(2)3/h4-13,16,20-25,30,43H,14-15,17-19H2,1-3H3,(H,44,50)(H,45,51)(H,41,42,46)/b8-5+
• InChIKey: AWZWOMPLEBTAGQ-VMPITWQZSA-N
• SMILES: CC1=C(C=C(C=C1)NC(=O)C2=CC3=C(C=C2)C=NC=C3)C(=O)NC4=CN=C(N=C4)NC5=CC(=CC=C5)NC6CCN(CC6)C(=O)/C=C/CN(C)C

BLK-IN-2（Cat No.:I044057）is a potent and selective inhibitor of B lymphoid tyrosine kinase (BLK), a Src-family kinase predominantly expressed in B cells and pancreatic β-cells. By targeting BLK, this compound interferes with B-cell receptor (BCR) signaling, which is essential for B-cell development, activation, and survival. BLK-IN-2 is particularly valuable in immunology and oncology research, especially in studies related to autoimmune diseases and B-cell malignancies such as chronic lymphocytic leukemia (CLL). It also supports investigation into the role of BLK in insulin secretion and metabolic regulation, offering insights into immune-metabolic interactions.